Cardio-oncology & otherCohort study

Plasma Proteins Associated With the Immune Response to Anthracycline Cardiotoxicity in Patients With Hematologic Malignancies

Circ Heart FailPublished

  • prospectively enrolled cohort
  • aptamer-based proteomics platform
  • validation in a second patient cohort
  • mouse model of delayed doxorubicin cardiotoxicity

Authors' conclusion

Preanthracycline levels of the plasma immunologic proteins CPVL and PIGR were associated with a subsequent decline in cardiac function, representing potentially new inflammatory biomarkers of anthracycline cardiotoxicity.

Study context

Population
Patients with hematologic malignancies treated with anthracycline chemotherapydiscovery cohort 34 · validation cohort 32
Participants
34 vs 32
Exposure
The correlation between protein levels and change in left ventricular ejection fraction
  • discovery cohortn = 34
  • validation cohortn = 32

Main finding

As reported in the abstract

Correlation of baseline plasma PIGR and CPVL with subsequent decline in left ventricular ejection fraction · baseline (before anthracycline chemotherapy)

PIGR: R

−0.74

PIGR: P

=0.0022

CPVL: R

−0.74

CPVL: P

=0.0022

Observational data: associations, not effects.

Further findings

Confirmation in human plasma and mice

Findings were confirmed in human plasma samples using ELISA or Western blot, and similar changes in proteins were observed in mice treated with doxorubicin

Circulating IgA + B cells in mice

doxorubicin treatment was associated with increased circulating levels of IgA + (immunoglobulin A) B cells in mice, which similarly correlated with the decline in left ventricular ejection fraction

Overall survival and progression-free survival

The highest quartile of PIGR and CPVL levels was associated with decreased overall survival but not progression-free survival

Original publication

Plasma Proteins Associated With the Immune Response to Anthracycline Cardiotoxicity in Patients With Hematologic Malignancies. Circ Heart Fail. Published 27 August 2026. doi:10.1161/circheartfailure.125.013683

Summarised from the published abstract; every number is checked against it